Supreme Court agrees to review ‘skinny labeling’ and generic drug access

What's new in pharma

January 16, 2026 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

J. Scott Applewhite/AP STAT+ | Supreme Court agrees to review 'skinny labeling' and generic drug access Skinny labeling, which amounts to a carve-out, is one way that Congress attempted to foster more competition to benefit consumers. By Ed Silverman STAT+ | JPM Week 2026 is over. It was fantastic. Here's why In this week's "Adam's Biotech Scorecard," Adam explains why there's a lot to be excited about in the sector right now. By Adam Feuerstein STAT+ | Opinion: CMS' new MAHA ELEVATE innovation model has a fundamental flaw CMS's new MAHA ELEVATE innovation model seeks to address chronic disease. But it leaves the door open for pseudoscience. By Vishal Khetpal Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Democrats say America's role as a scientific leader is slipping, while Republicans remain unworried A new survey by the Pew Research Center also highlights a partisan split on many key issues, including the country's scientific standing globally. By Anil Oza

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser